XtalPi Receives Initial Payment Under Agreement With Dovetree
(RTTNews) - XtalPi Holdings said, in late June 2025, Shenzhen XtalPi Technology, an indirect subsidiary of the company, and DoveTree Medicines and its affiliates entered into a definitive agreement, under which the Group will use its end-to-end AI drug discovery platform through integrated AI + robotics technology to discover and develop small molecule and antibody drug candidates for multiple targets selected by DoveTree. The Group has received an initial payment of $51 million under the Definitive Agreement.
The Group is entitled to receive a further payment of $49 million, and is eligible to receive potential regulatory and commercial milestone payments, as well as potential royalties.
For More Such Health News, visit rttnews.com.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.